RA Capital Management

Invests in healthcare, life sciences.

RA Capital Management

Invests in healthcare, life sciences.

Overview

RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.

Work here?Claim your company

About RA Capital Management

Simplify's Rating

Why RA Capital Management is rated

B+

Rated A on Competitive Edge

Rated A on Growth Potential

Rated C on Differentiation

Industries

Data & AnalyticsVenture CapitalHealthcare

Company Size

N/A

Company Stage

N/A

Total Funding

$40.9B

Headquarters

Boston, Massachusetts

Founded

2001

Get referred to RA Capital Management

See people who can refer or advise you

Simplify's Take

What believers are saying

RA Capital led Tyra's $400 million September 2026 offering, showing deep syndicate influence.
September 2026 rounds for Solstice Oncology, Tectora, and Typewriter confirm active deal access.
AbbVie's June 2026 acquisition of Apogee and 2024 Aliada validate exit generation.

What critics are saying

Yale won a July 24, 2026 jury verdict against RA Capital for trade secret theft.
August 24, 2026 judgment formalized a $4 million award and contract breach finding.
A growing September 2026 financing binge increases exposure if multiple portfolio bets miss clinical endpoints.

What makes RA Capital Management unique

Peter Kolchinsky's team combines biotech diligence with multi-stage capital across private and public markets.
RA Capital financed 70 approved drugs and backed 125 IPOs through 2026.
Its 200-plus person platform adds structured capital, company creation, and commercialization support.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$40.9B

Above

Industry Average

Funded Over

0 Rounds

Benefits

Remote Work Options
Flexible Work Hours
Professional Development Budget

Company News

Business Wire

Oct 13th, 2026

Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

Lake Oconee Breeze

Sep 30th, 2026

Sagimet Biosciences prices $115M stock offering for Phase 3 acne trial and denifanstat pre-launch

Sagimet Biosciences has priced an underwritten offering of $115 million in Series A common stock and pre-funded warrants. The clinical-stage biopharmaceutical company will sell 8,750,010 shares at $10.00 per share, along with pre-funded warrants to purchase 2,750,010 shares at $9.9999 each. Commodore Capital is leading the financing, with participation from RA Capital Management, Spruce Street Capital, BVF Partners, and other institutional investors. The offering is expected to close on 1 October 2026. Sagimet plans to use the proceeds to fund a Phase 3 clinical trial for denifanstat in acne, pre-launch activities, advance its TVB-3567 programme through Phase 2, and support general corporate purposes. The company develops novel therapeutics targeting dysfunctional metabolic and fibrotic pathways.

Business Wire

Sep 17th, 2026

Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C fundin...

Business Wire

Sep 16th, 2026

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and ...

Yahoo Finance

Sep 16th, 2026

Circle Pharma raises $92.5M Series E led by The Column Group to advance oral cyclin D1 inhibitor into clinic

Circle Pharma has raised $92.5 million in a Series E financing round led by The Column Group, with participation from Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly and Company. The South San Francisco-based clinical-stage biopharmaceutical company will use the funds to advance CID-165, a first-in-class oral macrocyclic cyclin D1 RxL inhibitor, into clinical development. CID-165 is expected to enter clinical trials in Q1 2027 for patients with ER-positive breast cancer. The drug has shown strong anti-tumour activity in preclinical cancer models, both as a monotherapy and in combination with existing treatments. The financing will also support development of Circle Pharma's broader pipeline of cyclin-targeted macrocycles.

Recently Posted Jobs